Back Hepatitis C

Hepatitis C

AASLD 2012: Sofosbuvir + GS-5885 + Ribavirin Shows High Early Response Rates for Genotype 1 HCV

The hepatitis C virus polymerase inhibitor sofosbuvir produces high rates of sustained virological response for genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data from the ELECTRON trial presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.alt

AASLD 2012: Sofosbuvir + Daclatasvir Dual Regimen Cures Most Patients with HCV Genotypes 1, 2, or 3

A 12-week once-daily regimen of 2 direct-acting hepatitis C drugs -- sofosbuvir (formerly GS-7977) and daclatasvir (formerly BMS-790052) -- produced sustained virological response rates for treatment-naive patients in the 90% to 100% range, and appeared effective regardless of HCV subtype, IL28B pattern, or use of ribavirin, according to a late-breaker presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston. The developers are not planning further studies of this combination, however, leaving its fate uncertain. alt

AASLD 2012: Abbott Interferon-free Combination 'Promising' in Harder-to-treat People with Hep C

Over 79% of previously untreated and null-responder patients with genotype 1a hepatitis C achieved a sustained virological response 12 weeks after completing treatment with an interferon-free combination of 2 or 3 direct-acting antiviral agents developed by Abbott (ABT-450, ABT-267, and/or ABT-333), investigators reported at the American Association for the Stualtdy of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.

AASLD 2012: Daclatasvir + Asunaprevir + BMS-791325 Cures Hard-to-treat Hepatitis C Patients

Twelve weeks of treatment with a 3-drug combination of new hepatitis C direct-acting antivirals that included neither pegylated interferon nor ribavirin led to sustained virological response 12 weeks after completion of treatment (SVR12) in up to 94% of previously untreated patients with hepatitis C genotype 1 in a preliminary Phase 2 trial with 16 patients, Gregory Everson from the University of Colorado reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.alt

Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee

The American Association for the Study of Liver Diseases Liver Meeting is the premier annual U.S. conference on althepatology, covering all aspects of liver disease including viral hepatitis, fatty liver, hepatocellular carcinoma, and liver transplantation. Kicking off the meeting on Saturday, AASLD President Guadalupe Garcia-Tsao offered a media overview of some highlights selected from the more than 2000 abstracts to be presented during the week.

National Medical Association Releases Report on Hepatitis C Among African Americans

The National Medical Association, the largest medical organization representing African American physicians and their patients, has issued a new report on hepatitis C virus (HCV) infection among Black Americans, emphasizing the need for increased awareness, more screening of this population, and broader inclusion of African Americans in clinical trials.

alt

AASLD 2012: High Rate of Response to Daclatasvir and Asunaprevir in Harder-to-treat Hep C Patients

Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb (BMS) to treat hepatitis C was highly effective in curing the infection in previous null responders with HCV genotype 1b infection, some new antiviral drugs may still need to be administered with interferon in harder-to-treat patients with genotype 1a, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston.alt

AASLD 2012: Reducing Ribavirin, Adding EPO Both Manage Anemia in Hep C Patients on Boceprevir

Chronic hepatitis C patients being treated with boceprevir (Victrelis) plus pegylated interferon and ribavirin can effectively manage drug-induced anemia, either by ribavirin dose reduction or addition of erythropoietin (EPO), without compromising treatment effectiveness, according to a presentation at theAmerican Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.alt

AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis

The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston. Another analysis from the same trial showed good outcomes for people with liver fibrosis.alt